Exploratory efficacy endpoints in the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA)

Vaccine. 2017 Dec 18;35(51):7078. doi: 10.1016/j.vaccine.2017.10.056.

Authors

Chris Webber¹, Michael Patton², Marc J M Bonten³; CAPiTA Study Group⁴

Affiliations

¹ Pfizer Vaccine Clinical Research and Development, Peral River, NY, USA. Electronic address: Chris.Webber@pfizer.com.
² Pfizer Vaccine Clinical Research and Development, Maidenhead, UK. Electronic address: michael.patton@pfizer.com.
³ Julius Center for Health Sciences and Primary Care, UMC Utrecht, Netherlands. Electronic address: M.J.M.Bonten@umcutrecht.nl.
⁴ Julius Center for Health Sciences and Primary Care, UMC Utrecht, Netherlands.

PMID: 29195607
DOI: 10.1016/j.vaccine.2017.10.056

No abstract available

Publication types

Letter

MeSH terms

Adult
Antigens, Bacterial / urine
Bacteremia / prevention & control
Clinical Trials as Topic
Community-Acquired Infections / prevention & control*
Humans
Immunization
Pneumococcal Vaccines / immunology*
Pneumococcal Vaccines / therapeutic use
Pneumonia, Pneumococcal / prevention & control*
Serogroup

Substances

13-valent pneumococcal vaccine
Antigens, Bacterial
Pneumococcal Vaccines